Navigation Links
Mesa Laboratories, Inc. Added to the Russell Microcap Index
Date:7/7/2008

LAKEWOOD, Colo., July 7 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: MLAB) announced today that it was added to the Russell Microcap(R) Index when Russell Investments reconstituted its comprehensive family of U.S. indexes on June 27, 2008.

Membership in the Russell Microcap, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.

"We are pleased with our inclusion in this index, which reflects our continued positive momentum of sales and earnings," said John J. Sullivan, President and COO. "Russell is an industry leader for stock indexes, and we expect our inclusion will generate greater interest in our stock among institutional investors."

Annual reconstitution of Russell indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000(R) Index and Russell Microcap. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

About Russell:

Russell Investments aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $213 billion in asse
'/>"/>

SOURCE Mesa Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
5. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
10. Bond Laboratories, Inc. Announces 2-for-1 Forward Split
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... of power morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive ... 450 new signatures since the end of October, Bernstein ... had signed the petition as of November 21st, 2014. ... 31st, when 86,042 supporters had signed on to the ...
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... filed on behalf of patients who allegedly developed Type ... forward in the federal multidistrict litigation now underway in ... LLP reports. According to court documents, the litigation will ... 10:00 a.m. The Court has directed Lead Counsel for ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident attorney in ... with the option of leaving an online review using ... and easy to navigate website that has recently been ... allows clients to research the Hastings and Hastings law ... when retaining an attorney. Those who have been injured ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
... treatment for women that cuts off blood flow to ... appropriate treatment for women in a Clinical Therapeutics article ... England Journal of Medicine . "UFE (also called ... and minimally invasive option for women to consider. This ...
... , SAN FRANCISCO, Aug. 13 Nile Therapeutics, ... of novel therapeutics for heart failure patients, today announced its second quarter ... , , For the second quarter of 2009, ... share, compared to a net loss of approximately $3.8 million, or $0.16 ...
... , , DENVER, Aug. ... BDMS ) , operators of PERFECT TEETH ... and six months ended June 30, 2009. For the quarter ended ... 2.0%, to $15.2 million. Net revenue increased $93,000, or 1.1%, to ...
... areas of the brain needed to perceive feelings, study ... drinking can affect the ability to recognize other people,s ... used functional MRI to monitor brain activity in 15 ... faces with positive or negative emotional expressions. The brain ...
... , GUANGZHOU, China, Aug. 13 ... Medicine" or "the Company"), a developer,and a leading distributor ... (TCM), nutritional and dietary supplements, and,medical devices and medical ... Second Quarter 2009 Highlights:, ...
... , New England Journal of Medicine Highlights ... Decrease Hysterectomy Rate in United States , , ... invasive interventional radiology treatment for women that cuts off blood flow ... treatment for women in a Clinical Therapeutics article in the Aug. ...
Cached Medicine News:Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 2Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 2Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 2Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 3Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 5Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 6Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 7Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 8Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 9Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 10Health News:Boozing Blunts Ability to Read Faces 2Health News:China Medicine Announces Second Quarter 2009 Results 2Health News:China Medicine Announces Second Quarter 2009 Results 3Health News:China Medicine Announces Second Quarter 2009 Results 4Health News:China Medicine Announces Second Quarter 2009 Results 5Health News:China Medicine Announces Second Quarter 2009 Results 6Health News:China Medicine Announces Second Quarter 2009 Results 7Health News:China Medicine Announces Second Quarter 2009 Results 8Health News:China Medicine Announces Second Quarter 2009 Results 9Health News:China Medicine Announces Second Quarter 2009 Results 10Health News:China Medicine Announces Second Quarter 2009 Results 11Health News:China Medicine Announces Second Quarter 2009 Results 12Health News:China Medicine Announces Second Quarter 2009 Results 13Health News:China Medicine Announces Second Quarter 2009 Results 14Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 2Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 3Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 4Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 5
(Date:11/21/2014)... Nov. 21, 2014 Clementia ... Medicines Agency (EMA) has granted Orphan Medicinal ... product candidate, for the treatment of fibrodysplasia ... severely disabling genetic disease characterized by painful, ... and new abnormal bone formation. This process, ...
(Date:11/21/2014)... IRVINE, Calif. , Nov. 20, 2014  Edwards ... leader in the science of heart valves and hemodynamic ... corporate giving in 2014 to support a strong launch ... Heartbeat Matters , and to improve the global communities ... In 2014, Edwards, global corporate giving will exceed $8 ...
(Date:11/21/2014)... /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced today ... be presenting at the 26 th Annual Piper Jaffray ... New York . The formal presentation is scheduled ... addition, Mr. Krakauer and Jorgen B. Hansen , President ... the day. An audio webcast will be ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... the best of both worlds, the ... is the latest addition to the ... bipolar cautery instruments for ophthalmic surgery. ... extrusion aspiration and backflush functionality in ...
...
...
Medicine Products: